{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:49:53Z","timestamp":1778089793937,"version":"3.51.4"},"reference-count":41,"publisher":"American Diabetes Association","issue":"8","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>Research on \u03b2-cell autoimmunity in cystic fibrosis (CF)\u2013related diabetes (CFRD) is still rare. We aimed to analyze the frequency of \u03b2-cell autoimmunity and the influence on age at diabetes onset, insulin requirement, type of insulin therapy, and hypoglycemic or ketoacidotic events in patients with CFRD compared with antibody-negative patients with CFRD in the Diabetes Patienten Verlaufsdokumentation (DPV) registry.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESEARCH DESIGN AND METHODS<\/jats:title><jats:p>We analyzed data of 837 patients with CFRD in the German\/Austrian DPV database by multivariable mixed-regression modeling.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>In our cohort, 8.5% of patients with CFRD (n = 72) were found to be \u03b2-cell antibody positive. There was a female preponderance in this patient group: 65.3 vs. 57.6%. Diabetes onset (median [interquartile range]) was earlier (14.00 [10.15\u201315.90] vs. 16.10 [13.50\u201321.20] years; P &amp;lt; 0.005), and insulin dose\/kg body weight was higher (0.95 [0.61\u20131.15] vs. 0.67 [0.33\u20131.04] IU\/kg; P &amp;lt; 0.05). There were also differences in the type of insulin treatment. Insulin pump therapy was used significantly more often in patients with CFRD with \u03b2-cell autoimmunity (18.2 vs. 6.4%; P &amp;lt; 0.05). The differences for multiple daily injections (ICT) and conventional therapy (CT) were not significant (ICT: 67.7 vs. 79.0%; CT: 15.2 vs. 14.6). Oral antidiabetic agents were rarely used in both groups. Rate of severe hypoglycemia with coma and rate of ketoacidosis were higher in antibody-positive patients (hypoglycemia with coma: 8.0 vs. 1.4, P &amp;lt; 0.05; ketoacidosis: 9.3 vs. 0.9, P &amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Presence of \u03b2-cell autoantibodies in our cohort of patients with CFRD (8.5%) appeared to be greater than in the general population and was associated with female sex, earlier onset of diabetes, and higher insulin requirement. Insulin pump therapy was used significantly more often in patients with \u03b2-cell antibodies. Severe hypoglycemia and ketoacidosis were significantly more frequent in CFRD with \u03b2-cell autoimmunity compared with \u03b2-cell antibody-negative patients with CFRD.<\/jats:p><\/jats:sec>","DOI":"10.2337\/dc16-0020","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T03:33:51Z","timestamp":1465270431000},"page":"1338-1344","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":25,"title":["Does \u03b2-Cell Autoimmunity Play a Role in Cystic Fibrosis\u2013Related Diabetes? Analysis Based on the German\/Austrian Diabetes Patienten Verlaufsdokumentation Registry"],"prefix":"10.2337","volume":"39","author":[{"given":"Katja","family":"Konrad","sequence":"first","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, University of Cologne, Cologne, Germany"},{"name":"Department of Pediatric and Adolescent Medicine, Elisabeth-Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kapellen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Leipzig, Leipzig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eggert","family":"Lilienthal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Bochum, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Prinz","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, University of Linz, Linz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Thon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hannover Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst","family":"Rietschel","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, University of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagobert","family":"Wiemann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Magdeburg, Magdeburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard W.","family":"Holl","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany"},{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2016,6,6]]},"reference":[{"key":"2022031301015955800_B1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ppul.21495","article-title":"Cystic fibrosis related diabetes (CFRD)--the end stage of progressive insulin deficiency","volume":"46","author":"Hameed","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"2022031301015955800_B2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2337\/dc12-0807","article-title":"Comparison of cystic fibrosis-related diabetes with type 1 diabetes based on a German\/Austrian Pediatric Diabetes Registry","volume":"36","author":"Konrad","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031301015955800_B3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/dmrr.2429","article-title":"Cystic fibrosis-related diabetes compared with type 1 and type 2 diabetes in adults","volume":"29","author":"Konrad","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031301015955800_B4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jpeds.2004.12.039","article-title":"Epidemiology of cystic fibrosis-related diabetes","volume":"146","author":"Marshall","year":"2005","journal-title":"J Pediatr"},{"key":"2022031301015955800_B5","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/EJE-14-0644","article-title":"Management of endocrine disease: Cystic fibrosis-related diabetes: novel pathogenic insights opening new therapeutic avenues","volume":"172","author":"Barrio","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2022031301015955800_B6","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031301015955800_B7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0046-8177(84)80191-4","article-title":"Endocrine pancreas in cystic fibrosis: an immunohistochemical study","volume":"15","author":"Iannucci","year":"1984","journal-title":"Hum Pathol"},{"key":"2022031301015955800_B8","first-page":"1267","article-title":"Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis","volume":"81","author":"Couce","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301015955800_B9","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1463-1326.2010.01250.x","article-title":"Managing diabetes in cystic fibrosis","volume":"12","author":"Laguna","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"2022031301015955800_B10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00005176-199708000-00010","article-title":"Insulin resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis patients","volume":"25","author":"Holl","year":"1997","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2022031301015955800_B11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1210\/jc.2008-2186","article-title":"Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis","volume":"94","author":"Blackman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301015955800_B12","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.2337\/dc11-2327","article-title":"No relation between cystic fibrosis-related diabetes and type 1 diabetes autoimmunity","volume":"35","author":"Gottlieb","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031301015955800_B13","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/db11-0674","article-title":"Rituximab selectively suppresses specific islet antibodies","volume":"60","author":"Yu","year":"2011","journal-title":"Diabetes"},{"key":"2022031301015955800_B14","doi-asserted-by":"crossref","first-page":"17040","DOI":"10.1073\/pnas.0705894104","article-title":"The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes","volume":"104","author":"Wenzlau","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022031301015955800_B15","doi-asserted-by":"crossref","first-page":"e000076","DOI":"10.1136\/bmjdrc-2014-000076","article-title":"Presence of anti-GAD in a non-diabetic population of adults; time dynamics and clinical influence: results from the HUNT study","volume":"3","author":"S\u00f8rgjerd","year":"2015","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2022031301015955800_B16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/dc06-0711","article-title":"Signs of beta-cell autoimmunity in nondiabetic schoolchildren: a comparison between Russian Karelia with a low incidence of type 1 diabetes and Finland with a high incidence rate","volume":"30","author":"Kondrashova","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031301015955800_B17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1399-5448.2010.00697.x","article-title":"\u03b2-cell autoimmunity in overweight non-diabetic youth: any implications?","volume":"12","author":"Libman","year":"2011","journal-title":"Pediatr Diabetes"},{"key":"2022031301015955800_B18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jcf.2013.03.001","article-title":"ZnT8 antibodies in patients with cystic fibrosis: an expression of secondary beta-cell damage?","volume":"12","author":"Bizzarri","year":"2013","journal-title":"J Cyst Fibros"},{"key":"2022031301015955800_B19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/pedi.12178","article-title":"ISPAD Clinical Practice Consensus Guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents","volume":"15","author":"Moran","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"2022031301015955800_B20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s001120170107","article-title":"Perzentile f\u00fcr Body-mass-Index f\u00fcr das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben","volume":"149","author":"Kromeyer-Hauschild","year":"2001","journal-title":"Monatsschr Kinderheilkd"},{"key":"2022031301015955800_B21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00431-007-0586-9","article-title":"Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in Germany and Austria during the last decade","volume":"167","author":"Gerstl","year":"2008","journal-title":"Eur J Pediatr"},{"key":"2022031301015955800_B22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1399-5448.2009.00583.x","article-title":"Assessment and management of hypoglycemia in children and adolescents with diabetes","volume":"10","author":"Clarke","year":"2009","journal-title":"Pediatr Diabetes"},{"key":"2022031301015955800_B23","first-page":"1457","article-title":"Diabetic ketoacidosis in cystic fibrosis","volume":"146","author":"Atlas","year":"1992","journal-title":"Am J Dis Child"},{"key":"2022031301015955800_B24","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.diabres.2015.07.003","article-title":"Thyroid function and autoimmunity in children and adolescents with type 1 diabetes mellitus","volume":"110","author":"Riquetto","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031301015955800_B25","first-page":"113","article-title":"Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Effect of age, gender and HLA type","volume":"52","author":"Holl","year":"1999","journal-title":"Horm Res"},{"key":"2022031301015955800_B26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1530\/eje.1.02344","article-title":"Spontaneous hypoglycemia in patients with cystic fibrosis","volume":"156","author":"Battezzati","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2022031301015955800_B27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/pedi.12174","article-title":"ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and management of hypoglycemia in children and adolescents with diabetes","volume":"15","author":"Ly","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"2022031301015955800_B28","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.2337\/dc15-0780","article-title":"Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the U.S., Austria, and Germany","volume":"38","author":"Maahs","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301015955800_B29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/pedi.12154","article-title":"The International Society of Pediatric and Adolescent Diabetes guidelines for management of diabetic ketoacidosis: Do the guidelines need to be modified?","volume":"15","author":"Wolfsdorf","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"2022031301015955800_B30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1399-5448.2010.00728.x","article-title":"Predictors of diabetic ketoacidosis in children and adolescents with type 1 diabetes. Experience from a large multicentre database","volume":"12","author":"Fritsch","year":"2011","journal-title":"Pediatr Diabetes"},{"key":"2022031301015955800_B31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1399-5448.2008.00441.x","article-title":"A 2-yr national population study of pediatric ketoacidosis in Sweden: predisposing conditions and insulin pump use","volume":"10","author":"Hanas","year":"2009","journal-title":"Pediatr Diabetes"},{"key":"2022031301015955800_B32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jdiacomp.2010.05.003","article-title":"Diabetic keto-acidosis as a presentation of cystic fibrosis-related diabetes: a case report","volume":"25","author":"Eenkhoorn","year":"2011","journal-title":"J Diabetes Complications"},{"key":"2022031301015955800_B33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1399-5448.2008.00359.x","article-title":"A teenage girl with cystic fibrosis-related diabetes, diabetic ketoacidosis, and cerebral edema","volume":"9","author":"Swartz","year":"2008","journal-title":"Pediatr Diabetes"},{"key":"2022031301015955800_B34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2337\/diacare.23.1.126b","article-title":"HbA1c is not recommended as a screening test for diabetes in cystic fibrosis","volume":"23","author":"Holl","year":"2000","journal-title":"Diabetes Care"},{"key":"2022031301015955800_B35","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.diabet.2008.05.010","article-title":"No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes","volume":"34","author":"Godbout","year":"2008","journal-title":"Diabetes Metab"},{"key":"2022031301015955800_B36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcf.2015.03.013","article-title":"HbA1c as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Burgess","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2022031301015955800_B37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2014.05.006","article-title":"Adherence to clinical care guidelines for cystic fibrosis-related diabetes in 659 German\/Austrian patients","volume":"13","author":"Scheuing","year":"2014","journal-title":"J Cyst Fibros"},{"key":"2022031301015955800_B38","first-page":"136","article-title":"Medical care for children and adolescents with diabetes\u2014trends in the last 18 years","volume-title":"diabetesDE. German Health Report on Diabetes","author":"Holl","year":"2013"},{"key":"2022031301015955800_B39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1464-5491.2007.02311.x","article-title":"Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years","volume":"25","author":"Jakisch","year":"2008","journal-title":"Diabet Med"},{"key":"2022031301015955800_B40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1034\/j.1399-5448.2002.30103.x","article-title":"Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups","volume":"3","author":"Ahern","year":"2002","journal-title":"Pediatr Diabetes"},{"key":"2022031301015955800_B41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/pedi.12158","article-title":"Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes?","volume":"16","author":"Scheuing","year":"2015","journal-title":"Pediatr Diabetes"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/8\/1338\/626298\/dc160020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/8\/1338\/626298\/dc160020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T11:31:23Z","timestamp":1718623883000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/8\/1338\/37100\/Does-Cell-Autoimmunity-Play-a-Role-in-Cystic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,6]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,6,6]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-0020","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,6]]}}}